Anti-VASH1 Antibody

VASH1 was originally identified as an endothelium-derived vascular endothelial growth factor (VEGF) -inducible angiogenesis inhibitor that acts in a negative feedback manner. VASH1 mRNA is expressed brain, heart, kidney and placenta in the adult, with robust expression in various organs during embryonic development. VASH1 expression in tumor cells and tumor vasculature is silenced by methylation by increased expression of Zeste homolog 2 (EZH2) . The increase of EZH2 expression is induced by VEGF stimulation, leading to poor clinical prognosis. Recombinant adenovirus expressing VASH prevented tumor angiogenesis and inhibited tumor growth, suggesting that it may be a potentially valuable antitumor therapy in the clinic.

VASH1 antibody is predicted to not cross-react with other vasohibin protein family members. At least two isoforms are known to exist; this antibody will recognize only the long isoform.

VASH1 antibody was raised against a 19 amino acid synthetic peptide near the carboxy terminus of human VASH1. The immunogen is located within amino acids 290 - 340 of VASH1.

Preferentially expressed in endothelial cells (PubMed:15467828, PubMed:16707096) . Highly expressed in fetal organs (PubMed:15467828) . Expressed in brain and placenta, and at lower level in heart and kidney (PubMed:15467828) . Highly detected in microvessels endothelial cells of atherosclerotic lesions (PubMed:16707096) .

Tyrosine carboxypeptidase that removes the C-terminal tyrosine residue of alpha-tubulin, thereby regulating microtubule dynamics and function (PubMed:29146869) . Acts as an angiogenesis inhibitor: inhibits migration, proliferation and network formation by endothelial cells as well as angiogenesis (PubMed:15467828, PubMed:16488400, PubMed:16707096, PubMed:19204325) . This inhibitory effect is selective to endothelial cells as it does not affect the migration of smooth muscle cells or fibroblasts (PubMed:15467828, PubMed:16488400, PubMed:16707096) .

VASH1 antibody can be stored at 4 °C, stable for one year. Avoid repeated freeze-thaw cycles. Antibodies should not be exposed to prolonged high temperatures.